MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.790
+0.080
+4.68%
After Hours: 1.790 0 0.00% 16:34 10/17 EDT
OPEN
1.710
PREV CLOSE
1.710
HIGH
1.810
LOW
1.695
VOLUME
119.79K
TURNOVER
--
52 WEEK HIGH
4.070
52 WEEK LOW
1.440
MARKET CAP
131.81M
P/E (TTM)
-7.5527
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MEIP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MEIP News

  • The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
  • Benzinga.10/04 12:32
  • 16 Healthcare Stocks Moving In Friday's Pre-Market Session
  • Benzinga.10/04 12:21
  • 22 Stocks Moving in Friday's Pre-Market Session
  • Benzinga.10/04 11:41
  • The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
  • Benzinga.10/04 11:32

More

Industry

Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.62%

Hot Stocks

Name
Price
%Change

About MEIP

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
More

Webull offers MEI Pharma Inc (MEIP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.